Frazier Lifesciences Acquisition Return on Equity

Frazier Lifesciences Acquisition's return on equity stands at 18.67%. That is above the sector sector average of -4.03%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Frazier Lifesciences Acquisition sits higher the its sector benchmark (-4.03%) with a ROE of 18.67%. That is roughly 563.8% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A ROE of 18.67% for Frazier Lifesciences Acquisition means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how Frazier Lifesciences Acquisition's ROE evolved across reporting periods, while the comparison chart places FLAC next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.